Cannabis Stock News Daily Roundup December 18

0
Cannabis Stock News Daily Roundup December 18

Cannabis News

Beleave (OTCQX: BLEVF) has issued an update and clarification on its GMP certification process, which is designed to help companies prepare products for export. According to the company, Global Compliance has inspected and assessed its processes for the production of medical and recreational cannabis and determined that the facility meets all requirements for certification.

The Global Cannabis Partnership (GCP) says that it added seven new members as it continues to grow internationally, bringing its total membership number to 31. The new members are Cannvas MedTech, Compass Cannabis Clinic / Starbuds Canada, Constance Therapeutics, MediPharm Labs Corp., Nutrasource Pharmaceutical & Neutraceutical Services, StrainprintTM Technologies Ltd. and YSS by Solo. The GCP represents a cross-section of organizations that focus on the legal, adult-use recreational cannabis supply chain.

Garden Remedies, Massachusetts’ only cannabis company founded and led by a woman physician, reported significant expansion in 2018. The company was granted multiple new special permits for cannabis sales in Marlborough, Newton, Melrose and Fitchburg. In a statement, the company said that these permits will allow it “to expand its mission to help thousands more people by providing access to safe, legal and natural cannabis products.”

Namaste Technologies (OTCMKTS: NXTTF) has entered into an agreement to acquire common shares in cannabis delivery firm Pineapple Express Delivery. Upon completion of the deal, Namaste will own 49% of the outstanding common shares of Pineapple Express. As part of the deal, Namaste’s CEO Sean Dollinger will join the Pineapple Express board of directors. In a press statement, Namaste said it “believes that same-day delivery for medical and recreational cannabis through Pineapple Express’ platform will provide patients and consumers with added-value and the Company looks forward to the expansion of the platform across Canada.”

Aphria (NYSE: APHA) and Rapid Dose Therapeutics (CSE: DOSE) have agreed to introduce QuickStrip innovative delivery technology for the cannabis market in Germany. Aphria has been granted exclusive preferred rights to license, manufacture, distribute and sell Rapid Dose’s QuickStrip technology in Germany. QuickStrip is a fast-dissolving drug delivery system that offers a smoke-free choice to consumers. Aphria expects to produce and distribute CBD-only Quickstrips in Germany by spring 2019.